B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Vaxart (NASDAQ:VXRT) Inc on Tuesday, setting a price target of $16, which is approximately 72.04% above the present share price of $9.3.
Mamtani expects Vaxart Inc to post earnings per share (EPS) of -$0.08 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Vaxart, with an average price target of $17.67.
The analysts price targets range from a high of $20 to a low of $16.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $265 thousand and a net profit of -$8.54 million. The company's market cap is $1.02 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 34.2% and a 60.13% success rate.
Biota Holdings Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.